Search results for "syndromes"

showing 10 items of 399 documents

WHO-defined ‘myelodysplastic syndrome with isolated del(5q)’ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence …

2010

The 2008 World Health Organization (WHO) criteria were used to identify 88 consecutive Mayo Clinic patients with 'myelodysplastic syndrome with isolated del(5q)' (median age 74 years; 60 females). In all, 60 (68%) patients were followed up to the time of their death. Overall median survival was 66 months; leukemic transformation was documented in five (5.7%) cases. Multivariable analysis identified age >or=70 years (P=0.01), transfusion need at diagnosis (P=0.04) and dysgranulopoiesis (P=0.02) as independent predictors of shortened survival; the presence of zero (low risk), one (intermediate risk) or >or=2 (high risk) risk factors corresponded to median survivals of 102, 52 and 27 months, r…

AdultMaleCancer Researchmedicine.medical_specialtyIDH1Biology5q-World Health OrganizationPolymerase Chain ReactionGastroenterologyIDH2ironInternal medicineMyelodysplastic Syndrome with Isolated del(5q)medicineHumansSurvival rateAgedAged 80 and overThrombopoietin receptorHematologyMyelodysplastic syndromesferritinHematologyJanus Kinase 2Middle AgedPrognosismedicine.diseaseIsocitrate DehydrogenaseSurvival RateLeukemiaCell Transformation NeoplasticOncologyMyelodysplastic SyndromesMutationImmunologyChromosomes Human Pair 5Original ArticleFemaleChromosome DeletionReceptors ThrombopoietinLeukemia
researchProduct

Rare NLRP12 variants associated with the NLRP12-autoinflammatory disorder phenotype: an Italian case series.

2013

AdultMaleHeredityAdolescentIntracellular Signaling Peptides and Proteinsautoinflammatory disorder phenotype NLRP12TRAPSMiddle AgedCryopyrin-Associated Periodic SyndromesPedigreePhenotypeTreatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyMutationHumansFemaleGenetic Predisposition to DiseaseAdolescent; Adult; Child Preschool; Cryopyrin-Associated Periodic Syndromes; Female; Genetic Predisposition to Disease; Heredity; Humans; Immunosuppressive Agents; Intracellular Signaling Peptides and Proteins; Italy; Male; Middle Aged; Pedigree; Phenotype; Treatment Outcome; MutationChildPreschoolImmunosuppressive Agents
researchProduct

Antibody Response to Meningococcal Polysaccharides A and C in Patients with Complement Defects

1993

Patients with defects of terminal complement components are particularly exposed to the risk of developing neisserial infections and seem to respond poorly to meningococcal capsular polysaccharide (PS) C via natural immunization. The sole meningococcal PSC is. on the other hand, an excellent immunogen in normal people. Considering the great importance of vaccine prophylaxis for the prevention of meningococcal infections in patients with complement defects, it is crucial to study the antibody response to the sole meningococcal PS in these patients. We therefore analysed the levels of anti-PSA and PSC antibodies in the members of four families including patients with homozygous and heterozygo…

AdultMaleHeterozygoteTime FactorsAdolescentImmunologyNeisseria meningitidismedicine.disease_causeSerologyAntibody SpecificitymedicineHumansChildbiologyImmunogenicityNeisseria meningitidisHomozygotePolysaccharides BacterialVaccinationImmunologic Deficiency SyndromesGeneral MedicineMiddle AgedAntibodies BacterialComplement C8VirologyComplement C7PedigreeVaccinationImmunizationComplement Factor HFactor HAntibody FormationImmunologyHumoral immunitybiology.proteinFemaleAntibodyScandinavian Journal of Immunology
researchProduct

Social cognition dysfunctions in patients with epilepsy: Evidence from patients with temporal lobe and idiopathic generalized epilepsies

2015

Abstract Background and aim Despite an extensive literature on cognitive impairments in focal and generalized epilepsy, only a few number of studies specifically explored social cognition disorders in epilepsy syndromes. The aim of our study was to investigate social cognition abilities in patients with temporal lobe epilepsy (TLE) and in patients with idiopathic generalized epilepsy (IGE). Materials and methods Thirty-nine patients (21 patients with TLE and 18 patients with IGE) and 21 matched healthy controls (HCs) were recruited. All subjects underwent a basic neuropsychological battery plus two experimental tasks evaluating emotion recognition from facial expression (Ekman-60-Faces test…

AdultMaleIdiopathic generalized epilepsymedicine.medical_specialtyEmotionsNeuropsychological Testsbehavioral disciplines and activitiesIdiopathic generalized epilepsyBehavioral NeuroscienceEpilepsyCognitionSocial cognitionmedicineNeurobehavioral impairmentHumansNeuropsychological assessmentGeneralized epilepsyTemporal lobe epilepsySocial BehaviorPsychiatryEpilepsymedicine.diagnostic_testNeuropsychologyCognitionMiddle Agedmedicine.diseaseSocial cognitionTemporal LobeFacial ExpressionEpilepsy Temporal LobeSocial PerceptionNeurologyFaceEpilepsy syndromesSettore MED/26 - NeurologiaEpilepsy GeneralizedFemaleNeurology (clinical)EmpathyCognition DisordersPsychologypsychological phenomena and processesClinical psychologyEpilepsy & Behavior
researchProduct

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-fi…

2017

Myelodysplastic syndromes are characterised by ineffective erythropoiesis. Luspatercept (ACE-536) is a novel fusion protein that blocks transforming growth factor beta (TGF β) superfamily inhibitors of erythropoiesis, giving rise to a promising new investigative therapy. We aimed to assess the safety and efficacy of luspatercept in patients with anaemia due to lower-risk myelodysplastic syndromes.In this phase 2, multicentre, open-label, dose-finding study (PACE-MDS), with long-term extension, eligible patients were aged 18 years or older, had International Prognostic Scoring System-defined low or intermediate 1 risk myelodysplastic syndromes or non-proliferative chronic myelomonocytic leuk…

AdultMaleIneffective erythropoiesismyalgiamedicine.medical_specialtyPediatricsTime FactorsMaximum Tolerated DoseAnemiaActivin Receptors Type IIRecombinant Fusion ProteinsKaplan-Meier EstimateLower riskmedicine.disease_causeRisk AssessmentSeverity of Illness IndexDisease-Free SurvivalDrug Administration Schedule03 medical and health sciences0302 clinical medicineGermanyInternal medicineSeverity of illnessmedicineHumansProspective StudiesProspective cohort studyAdverse effectAgedProportional Hazards ModelsDose-Response Relationship Drugbusiness.industryMyelodysplastic syndromesAnemiaMiddle AgedPrognosismedicine.diseaseSurvival AnalysisActivinsImmunoglobulin Fc FragmentsTreatment OutcomeOncologyMyelodysplastic Syndromes030220 oncology & carcinogenesisFemalemedicine.symptombusiness030215 immunologyThe Lancet Oncology
researchProduct

Effects of myofascial release in erector spinae myoelectric activity and lumbar spine kinematics in non-specific chronic low back pain: Randomized co…

2019

Este artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://www.sciencedirect.com/science/article/abs/pii/S0268003318300330?via%3Dihub This is the pre-peer reviewed version of the following article: Arguisuelas, M.D., Lisón, J.F., Doménech-Fernández, J., Martínez-Hurtado, I., Salvador Coloma, P. & Sánchez-Zuriaga, D. (2019). Effects of myofascial release in erector spinae myoelectric activity and lumbar spine kinematics in non-specific chronic low back pain: randomized controlled trial. Clinical Biomechanics, vol. 63, pp. 27-33, which has been published in final form at https://doi.org/10.1016/j.clinbiomech.2019.02.009 Este es el pre-print del siguiente…

AdultMaleManipulation Spinalmedicine.medical_specialtySíndrome de dolor miofascial - Fisioterapia.Myofascial releaseParaspinal MusclesBiophysicsMyofascial pain syndromes - Physical therapy.ElectromyographySpinal manipulationlaw.invention03 medical and health sciences0302 clinical medicineLumbarDouble-Blind MethodRandomized controlled triallawmedicineHumansOrthopedics and Sports MedicineLow back painRange of Motion ArticularFasciaBackache - Treatment.MassageLumbar VertebraeRelaxation (psychology)medicine.diagnostic_testbusiness.industryElectromyographyPhysical therapy modalitiesDolor de espalda - Electromiografía.Lumbosacral Region030229 sport sciencesFasciaMiddle AgedBackache - Electromyography.Low back painBiomechanical PhenomenaMyofascial releasemedicine.anatomical_structurePhysical therapyFemalemedicine.symptomDolor de espalda - Tratamiento.businessLow Back Pain030217 neurology & neurosurgery
researchProduct

An Emerging Method to Assess Tear Film Spread and Dynamics as Possible Tear Film Homeostasis Markers

2021

This study aims to assess the performance of an analysis method to measure in vivo the movement speed of tear film particles post-blink as a measure of tear film spreading. Ocular surface parameter...

AdultMaleMaterials scienceAdolescentgenetic structuresMeasure (physics)Young Adult03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineHomeostasisHumansAnalysis methodAgedAged 80 and overBlinkingDynamics (mechanics)Meibomian GlandsMiddle AgedHealthy Volunteerseye diseasesSensory SystemsOphthalmologyTears030221 ophthalmology & optometryDry Eye SyndromesFemalesense organsOcular surface030217 neurology & neurosurgeryBiomedical engineeringCurrent Eye Research
researchProduct

Optic nerve decompression in trauma and tumor patients

1999

Optic nerve decompression is a procedure that is now receiving increasing clinical attention. However, there are currently no standardized treatment protocols in the therapy of traumatic or pressure insults to the nerve. The present retrospective study was designed to report our experience with microscopic endonasal transethmoid-sphenoid optic nerve decompression in 24 unilateral trauma cases and 11 unilateral skull base tumor patients. In general preoperative visual acuities in the trauma patients were worse than in the tumor patients. Following surgery, 9 of 11 tumor patients (82%) had at least some improvement of their vision, including 5 complete recoveries. In the group with traumatic …

AdultMaleMicrosurgerymedicine.medical_specialtygenetic structuresDecompressionEye diseasemedicine.medical_treatmentVisual impairmentVisual AcuityBlindnessSkull Base NeoplasmsPostoperative ComplicationsOptic Nerve DiseasesmedicineHumansCranial nerve diseaseOrbital FracturesCraniotomyAgedbusiness.industryNerve Compression SyndromesEndoscopyGeneral MedicineMiddle AgedDecompression Surgicalmedicine.diseaseSurgeryTreatment OutcomeOtorhinolaryngologyOtorhinolaryngologyOptic Nerve InjuriesOptic nerveFemaleNeurosurgerymedicine.symptombusinessEuropean Archives of Oto-Rhino-Laryngology
researchProduct

REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31.

2008

Contains fulltext : 71291.pdf (Publisher’s version ) (Closed access) Mutations in the receptor expression enhancing protein 1 (REEP1) have recently been reported to cause autosomal dominant hereditary spastic paraplegia (HSP) type SPG31. In a large collaborative effort, we screened a sample of 535 unrelated HSP patients for REEP1 mutations and copy number variations. We identified 13 novel and 2 known REEP1 mutations in 16 familial and sporadic patients by direct sequencing analysis. Twelve out of 16 mutations were small insertions, deletions or splice site mutations. These changes would result in shifts of the open-reading-frame followed by premature termination of translation and haploins…

AdultMaleMutation rateAdolescentGenotypeHereditary spastic paraplegiaDNA Mutational AnalysisBiologymedicine.disease_causeArticleCognitive neurosciences [UMCN 3.2]Gene duplicationGenotypemedicinePerception and Action [DCN 1]HumansCopy-number variationAge of OnsetMutation frequencyChildAgedAged 80 and overGeneticsMutationHereditary cancer and cancer-related syndromes [ONCOL 1]Spastic Paraplegia HereditaryInfantMembrane Transport ProteinsMiddle Agedmedicine.diseasePedigreePhenotypeChild PreschoolMutationFemaleNeurology (clinical)HaploinsufficiencyFunctional Neurogenomics [DCN 2]
researchProduct

Estimation de l’incidence des hémopathies malignes en France entre 1980 et 2012

2016

International audience; BACKGROUND:The classification of hematological malignancies (HMs) has changed in recent decades. For the first time, the French network of cancer registries (Francim) provides estimates for incidence and trends of HM in France between 1980 and 2012 for major HM subtypes.METHODS:Incidence was directly estimated by modeling the incidence rates measured in the cancer registry area. For each HM subtype, a "usable incidence period" was defined a priori, corresponding to the years for which all the registries collected them in a homogeneous way. For both sexes and each HM subtype, age-period-cohort models were used to estimate national incidence trends.RESULTS:Overall in F…

AdultMaleOncologyPediatricsmedicine.medical_specialtyRegistryAdolescentEpidemiologyChronic lymphocytic leukemiaFollicular lymphoma[SDV.CAN]Life Sciences [q-bio]/Cancer[ SDV.CAN ] Life Sciences [q-bio]/CancerHematological malignanciesYoung Adult03 medical and health sciences0302 clinical medicineNeoplasmsInternal medicinemedicineHumansRegistriesAgedAged 80 and overbusiness.industryMyelodysplastic syndromesIncidence (epidemiology)IncidencePublic Health Environmental and Occupational HealthCancer[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieHémopathies malignesMiddle AgedPlasma cell neoplasmmedicine.disease3. Good healthLymphomaCancer registryTendancesHematologic Neoplasms030220 oncology & carcinogenesisFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFranceTrendsbusinessRegistre de population030215 immunology
researchProduct